Growth pattern and final height in 21-hydroxylase deficiency

Indian Pediatrics

Volumn 44, Issue 10, 2007, Pages 771-773

  Bajpai, Anurag ^a   Pandey, R M ^a   Kabra, Madhulika ^a   Menon, P S N ^a,b  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b Department of Pediatrics   (Kuwait)

Author keywords

21 hydroxylase deficiency; Congenital adrenal hyperplasia; Glucocorticoids; Growth

Indexed keywords

GLUCOCORTICOID; STEROID 21 MONOOXYGENASE;

ARTICLE; BODY HEIGHT; CHILD GROWTH; CLINICAL ARTICLE; ENZYME DEFICIENCY; FEMALE; FOLLOW UP; HUMAN; MALE; MULTIVARIATE ANALYSIS; PATIENT MONITORING; RISK FACTOR; UNIVARIATE ANALYSIS;

ADOLESCENT; ADRENAL HYPERPLASIA, CONGENITAL; BODY HEIGHT; CHILD; CHILD DEVELOPMENT; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; RETROSPECTIVE STUDIES;

EID: 35648988472     PISSN: 00196061     EISSN: 00196061     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Eugster EA, Dimeglio LA, Wright JC, Freidenberg GR, Seshadri R, Pescovitz OH. Height outcome in congenital adrenal hyperplasia caused by 21-hydroxylase deficiency: a meta-analysis. J Pediatr 2001; 138: 26-32.
2. Bhaskaran S, Nair V, Kumar H, Jayakumar RV. Audit of care of patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency in a referral hospital in South India. Indian Pediatr 2006; 43: 419-423.
3. Silva IN, Kater CE, Cunha CF, Viana MB. Randomized control trial of growth effect of hydrocortisone in congenital adrenal hyperplasia. Arch Dis Child 1997; 77: 214-218.
4. Jaaskelainen J, Voutlainen R. Growth of patents with 21-hydroxylase deficiency: an analysis of factors influencing adult height. Pediatr Res 1997; 41: 30-33.
5. Bajpai A, Kabra M, Menon PSN. 21-Hydroxylase deficiency: clinical features, laboratory profile and pointers to diagnosis in Indian children. Indian Pediatr 2004; 41: 1226-1232.
6. Schimer BP, Parker KL. Adrenocorticotropic hormone; adrenocortical steroids and their synthetic analogs: Inhibitors of the synthesis and actions of adrenal cortical hormones. In: Goodman LS, Gilman A, eds. The pharmacological basis of therapeutics. New York: McGraw-Hill 1996; p 1459-1485.
7. Antoniazzi F, Arrigo T, Cistemino M, Galluzzi F, Bertelloni S, Pasquino AM, et al. End results in central precocious puberty with GnRH analog treatment: The data of the Italian study group for pathophysiology of puberty. J Pediatr Endocrinol Metab 2000; 13: 773-780.
8. Hamill PV, Dizd TA, Johnson CL. NCHS curves for children, birth-18 yr. United States Vital Health Statistics 1977; I-IV: 1-74.
9. Stikkelbroeck NM, Van't Hof-Grootenboer BA, Hermus RM, Otten BJ, Van't Hof MA. Growth inhibition by glucocorticoid treatment in salt-wasting 21-hydroxylase deficiency: in early infancy and (pre) puberty. J Clin Endocrinol Metab 2003; 88: 3525-3530.
10. Khadilkar VV, Khadilkar AV, Maskati GB. Impact of availability of oral hydrocortisone on growth of children with CAH. Indian J Pediatr 2005; 72: 301-303.